Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

14.35 +0.33 (+2.35%)
Streaming Delayed Price Updated: 3:40 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
1 Small-Cap Stock with Impressive Fundamentals and 2 We Question
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Analyst Expectations For 10x Genomics's Future
 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
What's Driving the Market Sentiment Around 10x Genomics?
 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For 10x Genomics
 
Via Benzinga
Q2 Earnings Highs And Lows: 10x Genomics (NASDAQ:TXG) Vs The Rest Of The Life Sciences Tools & Services Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its peers. 
Via StockStory
Topics Artificial Intelligence Economy
Bio-Techne, 10x Genomics, Lumen, EPAM, and ASGN Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics Economy
LGI Homes, Moderna, Fortrea, 10x Genomics, and Cogent Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S.... 
Via StockStory
Topics Economy Stocks
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Topics Bonds
1 Volatile Stock to Own for Decades and 2 That Underwhelm
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
Brookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Artificial Intelligence Economy
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know
A number of stocks traded in opposite directions in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index... 
Via StockStory
Topics Bonds Economy Stocks
TXG Q2 Deep Dive: Robust Product Demand and Cautious Outlook Amid Funding Uncertainty
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter’s... 
Via StockStory
Why 10x Genomics (TXG) Stock Is Falling Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.5% in the morning session after the company reported strong second-quarter results that surpassed Wall Street's expectations for both revenue... 
Via StockStory
Topics Earnings
10x Genomics (NASDAQ:TXG) Reports Upbeat Q2, Stock Soars
Biotech company 10x Genomics (NASDAQ:TXG) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter’s revenue guidance of... 
Via StockStory
10X Genomics Inc-Class A (NASDAQ:TXG) Surprises with Strong Q2 2025 Earnings and Revenue Beat
10X Genomics (TXG) reported strong Q2 2025 earnings, beating revenue and EPS estimates, sparking a 4.68% after-hours stock surge. Revenue hit $172.91M, up 22.8%, with EPS at $0.28 vs. expected loss.... 
Via Chartmill
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending... 
Via StockStory
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory
Topics Stocks World Trade
3 Unprofitable Stocks We’re Skeptical Of
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
3 Russell 2000 Stocks with Red Flags
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
Demystifying 10x Genomics: Insights From 8 Analyst Reviews
 
Via Benzinga
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services stocks,... 
Via StockStory
Topics Artificial Intelligence
Delta, Macy's, CECO Environmental, RadNet, and 10x Genomics Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran. 
Via StockStory
Topics Economy Government Stocks
1 Cash-Producing Stock with Exciting Potential and 2 to Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Be Wary Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Artificial Intelligence
TXG Q1 Earnings Call: Academic Funding Uncertainty Drives Guidance Withdrawal and Cost Reductions
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s... 
Via StockStory
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.